formed in the reaction mixtures, and CYP3A4 was found to be responsible for the hydroxylation of the N 6 -benzyl ring at position 5 leading to this compound.
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INTRODUCTION
Microsomal cytochrome P450 (CYP) enzymes in the liver contribute to the first steps of the metabolism of diverse xenobiotics, including various drugs. However, some drugs may have undesirable effects, such as the inhibition or induction of these enzymes.
Hence, interactions between CYPs and drugs can have profound effects, including (reportedly) drug toxicity (e.g. terfenadine, mibefradil) (Wilkinson, 1996; Welker et al., 1998) and, in several cases, sub-therapeutic concentrations of drugs in target tissues (Bachmann et al., 2004) . The principal human liver CYPs involved in drug biotransformation are CYP3A4, CYP2D6, CYP2C9, CYP2E1 and CYP1A2, although CYP2C19, CYP2A6, and CYP2B6 may also contribute significantly to the metabolism of some drugs or other xenobiotics (Anzenbacher and Anzenbacherová, 2001; Guengerich, 2005) . The potential effects of drugs on specific CYP enzyme activities are generally examined using in vitro bacterial systems, each containing single forms of CYP, and/or liver microsomal fractions (Phillips and Shephard, 1996) .
Olomoucine II is a C2,N9-substituted 6-(2-hydroxybenzylamino)purine (orthotopolin) inhibitor of cyclin-dependent kinases (CDKs). Such compounds have attracted considerable attention since they can inhibit CDK9, thereby blocking the cell division cycle of animal cells. Thus, there is a possibility that they could be used as antineoplastic drugs (Kryštof et al., 2002) , although little is currently known about the potential interactions between olomoucine II and human liver microsomal CYPs. Hence, in the study presented here the potential for the CDK inhibitor olomoucine II to influence the activities of the principal drug-metabolising CYPs of human liver microsomes (CYP3A4, CYP2C9, CYP2D6, CYP2E1, CYP1A2, CYP2A6, CYP2B6 and CYP2C19) was This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 27, 2009 as DOI: 10.1124 at ASPET Journals on October 20, 2017 dmd.aspetjournals.org Downloaded from DMD #25502 5 thoroughly evaluated. In addition, the potential ability of human liver microsomal CYPs to catalyse the formation of olomoucine II metabolites was studied, and a metabolite generated in in vitro reaction mixtures (2,5-dihydroxyroscovitine) was identified by tandem mass spectrometry.
MATERIALS AND METHODS
Materials
Chemicals
Olomoucine II (2-({6-[(2-hydroxybenzyl)amino]-9-isopropyl-9H-purine-2-yl}amino)butan-1-ol; CAS 500735-47-7) was obtained from Sigma Aldrich (Prague, Czech Republic), and two potential metabolites, 2,4-dihydroxy derivate of roscovitine, (2-({6-[(2,4-dihydroxybenzyl) amino]-9-isopropyl-9H-purine-2-yl}amino)butan-1-ol and 2,5-dihydroxy derivate of roscovitine, (2-({6-[(2,5-dihydroxybenzyl)amino]-9-isopropyl-9H-purine-2-yl}amino)butan-1-ol were synthesised as detailed in the following section (for structures see Figure 1 ). Diclofenac, 4'-hydroxydiclofenac, bufuralol, 1'-hydroxybufuralol and 6β-hydroxytestosterone were supplied by Ultrafine Chemicals (Salford, UK). 7-Ethoxy-4-(trifluoromethyl)coumarin was purchased from Fluka (Buchs, Switzerland). (S)-(+)-N-3-benzylnirvanol was supplied by BD Gentest (Woburn, MA, USA). All other chemicals were purchased from Sigma-Aldrich (Prague, Czech Republic).
Preparation of 2,4-dihydroxyroscovitine and 2,5-dihydroxyroscovitine derivatives
This article has not been copyedited and formatted. The final version may differ from this version. The precursors (2,6-dichloro-9-isopropylpurine, 2,4-dihydroxybenzylamine hydroiodide and 2,5-dihydroxybenzylamine hydrochloride) required for synthesising the possible olomoucine II metabolites were prepared as previously described (Otyepka et al., 2000; Doležal et al., 2006; Doležal et al., 2007) . The appropriate dihydroxybenzylamine isomers (1 mmol) for the metabolites were then added individually, together with triethylamine (6 mmol), to a suspension of 2,6-dichloro-9-isopropylpurine (1 mmol) in ethylacetate. Each reaction mixture was stirred at 78 °C for 5 hours, and then cooled to room temperature. Next, the precipitate was filtered off, washed with cold water (2x10 ml) and diethylether (3x10 ml), and then dried at 60 °C to constant weight. The resultant 2-chloro-6(dihydroxybenzyl)amino-9-isopropylpurines were further substituted with (R/S)-2-aminobutan-1-ol (160°C, 3h). The products, 2,4-dihydroxyroscovitine and 2,5-dihydroxyroscovitine, were purified by extraction in ethylacetate and crystallization from ethanol. Product identities were confirmed by: melting point determination on a Boetius stage, thin layer chromatography (TLC) using WF 254 silica gel 60 plates (Merck, Darmstadt, Germany), elemental analysis (C, H, and N) using a EA1108 CHN analyser (Fisons Instruments, San Carlos, CA, USA), and NMR spectroscopy using a Bruker Avance AV 300 spectrometer. were purchased from Cypex (Dundee, UK).
Microsomes and recombinant enzymes
Methods
Determination of P450 activities
The following activities of the selected human liver microsomal CYPs were assayed according to well-established protocols: CYP3A, testosterone 6β-hydroxylation (Guengerich et al., 1986) ; CYP2E1, p-nitrophenol hydroxylation (Tassaneeyakul et al., 1993) ; CYP2C9, diclofenac 4-hydroxylation (Crespi et al., 1998a) ; CYP1A2, 7-ethoxyresorufin O-deethylation ; CYP2D6, bufuralol 1´-hydroxylation (Crespi et al., 1998b) ; CYP2C19, S-mephenytoin 4´-hydroxylation (http://www.cypex.co.uk/2c19info.htm); CYP2A6, coumarin 7-hydroxylation (Waxman and Chang, 1998) and CYP2B6, 7-ethoxy-4-(trifluoromethyl) coumarin O-deethylation (Donato et al., 2004) . The CYP1A2, CYP2A6 and CYP2B6 activities were calculated from spectral data acquired with a TECAN GENios absorbance-fluorescenceluminescence reader (Tecan Austria, Vienna, Austria), while the activities of CYP2C9, CYP2D6, CYP2C19, CYP2E1, and CYP3A4 were determined by monitoring amounts olomoucine II-free controls. In addition, since some organic solvents can inhibit CYP activities, even in relatively low concentrations (Chauret et al., 1998; Busby et al., 1999) the organic solvent concentrations in the final reaction mixtures were generally less than 1% (v/v) and organic solvent controls without the tested compounds were included in all cases, under otherwise identical experimental conditions. Experimental conditions pmol P450 and 0.500 mg protein/ml for CYP1A2, 34 pmol P450 and 0.500 mg protein/ml for CYP2A6, 34 pmol P450 and 0.400 mg protein/ml for CYP2B6, 35 pmol P450 and 0.250 mg protein/ml for CYP2C9, 50 pmol P450 and 0.375 mg protein/ml for CYP2C19, 67.3 pmol P450 and 0.500 mg protein/ml for CYP2D6, 160 pmol P450 and 0.250 mg protein/ml for CYP2E1 and 100 pmol P450 with 0.297 mg protein/ml for CYP3A4.
The inhibitory effect of olomoucine II on each of the examined CYP activities was then evaluated by plotting its concentration against the activities, expressed as means (in nmol product/min/nmol P450) obtained from two parallel assays at each substrate concentration for which there was a between-duplicate difference lower than 15%. In each case when significant inhibition of a CYP was detected the inhibition constant (K i ) was determined by constructing Dixon plots, using the scientific graphing software Sigma Plot 8.0.2 (SPSS, Chicago, IL, USA) and data obtained from assays with three substrate concentrations (corresponding to 1/2K M, K M and 2K M ). The degree of CYP inhibition was then evaluated using Microsoft Excel.
Metabolite formation and its inhibition by carbon monoxide
The effects of carbon monoxide on rates of formation of the olomoucine II metabolite (2,5-dihydroxyroscovitine) identified in analyses described below catalysed by the CYPs in the microsomal preparations were also assessed, as follows. Portions of the preparations containing 250 pmol of CYPs were incubated in 1 ml of a 50 mM potassium phosphate buffer (pH 7.4) containing an NADPH-generating system (0.5 mM NADP, 3.7 mM isocitric acid, and 0.5 unit/ml isocitric acid dehydrogenase) and 5 mM 
Inhibition of microsomal olomoucine II metabolism by specific inhibitors of individual CYP enzymes
In another series of assays we examined the effects on olomoucine II metabolite formation of the following specific inhibitors of CYP1A2, CYP2C9, CYP3A4, CYP2E1, CYP2D6, CYP2A6, CYP2B6 and CYP2C19 activity: furafylline (22.5 (Baldwin et al., 1995; Newton et al., 1995; Dierks et al., 2001; Goldstein et al., 1994 , Suzuki et al., 2002 . In these experiments each of the inhibitors 
Identification of the olomoucine II metabolite by mass spectrometry
To assess the possibility that interactions between olomoucine II and enzymes in the human liver microsomal preparations may result in the production of metabolites, olomoucine II was incubated with microsomal preparations (in triplicate) in 1 ml of TrisHCl buffer (pH 7.4) containing an NADPH-generating system (0.5 mM NADP, 3.7 mM isocitric acid and 0.5 unit/ml isocitric acid dehydrogenase), 5 mM MgCl 2 and 250 pmol of microsomal CYPs. After 10 min pre-incubation at 37°C, olomoucine II was added to the reaction mixtures to a final concentration of 50 
RESULTS
Olomoucine II inhibition of specific CYP enzyme activities in human liver microsomes
Olomoucine II had no apparent effects on the measured CYP2A6 and CYP2E1 activities, and only weakly interacted with CYP2B6, CYP2C8, CYP2C19 and CYP2D6.
These interactions are unlikely to be clinically relevant, since the enzymatic activities were not significantly influenced at physiologically relevant concentrations of the potential inhibitor (≤50 μ M; Fig. 2 ). However, olomoucine II clearly inhibited the enzymatic activities of CYP1A2, CYP2C9, and CYP3A4 at such concentrations (Fig. 2) .
This article has not been copyedited and formatted. The final version may differ from this version. Hence, Dixon plots were used to reveal the mechanisms behind these enzyme inhibitions, and to determine the respective K i values.
The Dixon plot for CYP1A2 indicates that it is subject to inhibition by olomoucine II via a mixed mechanism, with a K i of 50 µM (Fig. 4) . In contrast, the Dixon plot for CYP2C9 (Fig. 5) , together with the Lineweaver-Burk plot (not shown),
indicate that olomoucine II noncompetitively inhibits it, with an estimated K i of 75 µM.
The results also indicated that olomoucine II noncompetitively inhibits CYP3A4 (data not shown).
Metabolite identification by MS analysis
To assess the possibility that interactions between olomoucine II and CYP 
Influence of CO and specific CYP inhibitors on the formation of the olomoucine II metabolite
A carbon monoxide inhibition experiment corroborated the role of CYPs in the metabolism of olomoucine II, since the amount of 2,5-dihydroxyroscovitine formed was reduced by 85 % after carbon monoxide addition (results not shown). In addition, the effects of specific CYP inhibitors on formation of the metabolite were examined to identify the particular CYPs involved in olomoucine II metabolism. The only potent inhibitor of olomoucine II 5-hydroxylation appeared to be ketoconazole, a specific inhibitor of CYP3A4, which resulted in reductions in the amount of 2,5-dihydroxyroscovitine formed to ca. 1 % of control levels (results not shown).
Incubation of olomoucine II with recombinant CYP enzymes
This article has not been copyedited and formatted. The final version may differ from this version. and 3A4) confirmed the participation of CYP3A4 in olomoucine II 5-hydroxylation (Fig.   7 ).
DISCUSSION
The inhibition experiments showed that olomoucine II influenced the enzymatic activities of at least three CYPs: CYP1A2, CYP2C9 and CYP3A4 (Figures 2 and 3 ).
Standard Dixon plots, used to examine the character of enzyme inhibition, indicated that CYP1A2 enzymatic activity was subjected to a mixed inhibition mechanism, while olomoucine II noncompetitively inhibited CYP2C9 and CYP3A4. In each case, the IC 50
values were estimated to be in the range of tens of micromolar.
The results also revealed the formation of an olomoucine II-like metabolite in the liver microsomal fraction. Analysis of this metabolite by HPLC-(+)ESI-MS/MS showed that it possessed an extra hydroxyl group on the N 6 -benzyl substituent of the parent compound.
Comparative analysis of the potential olomoucine II metabolite with synthetic 2,5-dihydroxy-and 2,4-dihydroxy-roscovitine derivative standards confirmed the putative olomoucine II metabolite's 5-hydroxylation of the aromatic ring. Next, we were interested in identifying the particular CYP(s) that participated in the metabolite's formation. Initially, the role of CYP enzymes in the reaction was confirmed by using carbon monoxide to inhibit metabolite formation. Carbon monoxide is known to be a universal CYP inhibitor since it binds strongly to the heme iron, forming a complex that cannot mediate the catalytic reaction due to its inability to bind molecular oxygen (Cooper et al., 1977 We then used inhibitors of specific CYPs to identify the CYPs responsible for the formation of the olomoucine II metabolite. Of these, ketoconazole, a specific CYP3A4
inhibitor, was found to inhibit the hydroxylation of olomoucine II most strongly. In addition, the CYP3A4 enzyme was able to efficiently catalyse the 5-hydroxylation of the olomoucine II aromatic ring when olomoucine II was incubated with bactosomes expressing a single CYP. In contrast, there was a lack of, or little, metabolite formation when bactosomes expressing other important drug-metabolising CYPs were used ( Figure   7 ).
Nevertheless, the results concerning the metabolism of olomoucine II and its inhibition of CYP activities do not exclude the possibility that olomoucine could significantly interact with CYP3A4 (which was largely responsible for the metabolite's formation), or CYP1A2 and/or CYP2C9, which were also inhibited by olomoucine II in the microsomal fraction.
The results of a similar study with roscovitine (seliciclib), a 2-hydroxyroscovitine with structural similarities to olomoucine II (see Figure 1) , were published during the preparation of this manuscript (McClue and Stuart, 2008 here, and those published by McClue and Stuart (2008) , indicate that the potential for drug interactions involving these prospective antineoplastic compounds cannot be excluded, and should therefore be thoroughly tested.
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Figure 3
Olomoucine II inhibition of CYP1A2, CYP2C9 and CYP3A4 enzymatic activities.
Figure 4
Dixon plot of olomoucine II inhibition of microsomal CYP1A2 enzymatic activity.
Figure 5
Dixon plot of olomoucine II inhibition of microsomal CYP2C9 enzymatic activity. 
